A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering
Expert Reviews in Molecular Medicine · 2026
DOI: 10.1017/erm.2026.10052 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, 2026. Verfasst von Melike Aliciaslan und 2 weiteren Autor:innen. Beteiligte Einrichtung: https://ror.org/01m59r132Akdeniz University: Akdeniz Universitesi, Türkiye. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Genetic Therapy, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Akdeniz Üniversitesi.
Abstract (Originalsprache)
Background
CAR-T cell gene therapy has advanced from an experimental concept to a standard curative treatment for selected hematologic malignancies. Substantial clinical evidence has established CAR-T therapy as a cornerstone for relapsed/refractory B-cell malignancies and multiple myeloma, demonstrating durable, long-term remissions. In 2025, the U.S. Food and Drug Administration (FDA) eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirement, reflecting improved clinical management of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Yet, the widespread adoption of these therapies has unveiled a new landscape of long-term and next-generation challenges.
Methods
This review critically analyzes CAR-T therapy’s clinical trajectory and the bioengineering strategies redefining its safety, scalability, and translational potential.
Results
A major hurdle is therapeutic resistance driven by antigen escape, notably through alternative splicing and lineage switching. The emergence of long-term safety signals, specifically secondary T-cell malignancies, has necessitated rigorous surveillance, exemplified by the European Medicines Agency’s (EMA) mandate for lifelong patient monitoring. The therapeutic landscape is further complicated by histopathological and immunological barriers limiting the expansion and persistence of engineered cells. These include deficient T-cell trafficking, an immunosuppressive tumor microenvironment (TME), and antigen heterogeneity, which have historically constrained efficacy in solid tumors. To address these hurdles, the field is leveraging CRISPR-enhanced allogeneic platforms, cytokine-secreting armored CARs (TRUCKs), and logic-gated systems showing early clinical promise.
Conclusion
Building on these developments, we hypothesize that CAR-T therapy is undergoing a paradigm shift from single-target cytotoxicity toward a multi-functional, programmable framework capable of overcoming resistance, enhancing safety, and enabling effective penetration of solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- https://ror.org/01m59r132Akdeniz University: Akdeniz Universitesi, Türkiye.
ORCID-Profile: Melike Aliciaslan, Ezgi Erbasan, Salih Sanlioglu
Förderung
- Akdeniz Üniversitesi
Zitieren
APA
Aliciaslan, M., Erbasan, E., & Sanlioglu, S. (2026). A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering. Expert Reviews in Molecular Medicine. https://doi.org/10.1017/erm.2026.10052
Vancouver
Aliciaslan M, Erbasan E, Sanlioglu S. A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering. Expert Reviews in Molecular Medicine. 2026. doi:10.1017/erm.2026.10052
BibTeX
@article{Aliciaslan2026,
author = {Aliciaslan, Melike and Erbasan, Ezgi and Sanlioglu, Salih},
title = {A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
doi = {10.1017/erm.2026.10052}
}
EUVIMED